Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotatercept Add-on in Chinese Participants With PAH
NCT07899905Phase 4Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Nov 2026
- Primary completion
- Mar 2028
01
Overview
Phase 4, open-label, single-arm trial of sotatercept in pulmonary arterial hypertension (PAH), sponsored by Merck & Co. Primary endpoints: Change From Baseline in the 6-Minute Walk Distance at 24 weeks, Number of Participants Who Experience an Adverse Event at 37 weeks and 1 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
sotatercept
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT07899905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07899905.